PharmatrophiX Partners With Circular Genomics on Biomarkers
The collaboration applies blood-based circular RNA profiling to the Alzheimer's candidate LM11A-31 in an initial workstream.
Updated on Nov. 5, 2026 in Alzheimer’s
PharmatrophiX has entered a strategic collaboration with Circular Genomics to advance blood-based circular RNA biomarkers in neurodegenerative drug development. The first workstream will deploy Circular Genomics' CircPath profiling system in Alzheimer's research on LM11A-31, a first-in-class small molecule that acts on the p75 neurotrophin receptor.
Why it matters
Blood-based biomarkers could give drug developers a less invasive way to track how an experimental treatment changes biology over time. The partnership reflects growing interest in circular RNA as a potential indicator in neurodegenerative disease programmes.
The announcement cites no numerical results, with the work defined by the p75 neurotrophin receptor-targeting compound LM11A-31 and the research-use-only CircPath platform. Findings from the initial Alzheimer's workstream have not yet been reported, and the companies have not said when data will be available.
The players
PharmatrophiX
PharmatrophiX is a drug development company working on neurodegenerative therapies, including the p75 neurotrophin receptor-targeting compound LM11A-31.
Circular Genomics
Circular Genomics is a company that develops molecular profiling tools based on circular RNA, including the research-use-only CircPath system.
The details
Circular Genomics will use CircPath to examine baseline molecular differences and track biological pathway shifts during treatment. The companies plan to combine circular RNA findings with cognitive, clinical, imaging, proteomic, and Alzheimer's biomarker metrics, and they are considering HIV-associated dementia and progressive supranuclear palsy alongside Alzheimer's.
Timeline
November 5, 2026: Collaboration announced in publication.
Health Landscape
The partnership extends CircPath, a research-use-only circular RNA profiling system, into a named Alzheimer's drug programme for LM11A-31. It fits a broader push to find blood-based biomarkers that can track treatment response in neurodegenerative diseases where direct brain measurement is difficult.
The collaboration is at a research stage and does not change treatment access or daily health routines. Any future clinical trials of LM11A-31 would be needed before patients could be affected.
The takeaway
Blood-based biomarkers are becoming a key tool for judging whether experimental neurodegenerative drugs are working. Progress in this area will depend on whether the planned Alzheimer's workstream produces data that supports future clinical studies.
Further reading
For related coverage of disease research, see the Alzheimer’s section.
Source note: This article includes information reported by Pharmaceutical Technology.
